Mechanism of salt-mediated inhibition of lipoprotein lipase
The activity of lipoprotein lipase isolated from rat postheparin plasma has been determined with synthetic lipids, in the presence and absence of apoprotein of the natural substrate very low density lipoprotein, as a function of medium ion-pair ...
C J Fielding, P E Fielding
doaj
The Association of Adipokines and Myokines in the Blood of Obese Children and Adolescents with Lipoprotein Lipase rs328 Gene Variants. [PDF]
Shestopalov AV+10 more
europepmc +1 more source
Variants in ANGPTL4 and the Risk of Coronary Artery Disease [PDF]
Doria, Alessandro+2 more
core +1 more source
Studies on the Lipoprotein Lipases of Microorganisms
Teiiti Narasaki+2 more
openalex +2 more sources
Effect of estrogen on triacylglycerol metabolism: Inhibition of post‐heparin plasma lipoprotein lipase by phosvitin, an estrogen‐induced protein [PDF]
Jim Kelley+4 more
openalex +1 more source
Emulsions prepared by OPO (long‐chain fatty acids) exhibited the largest average particle size and greater stability compared to those with medium‐chain fat (coconut oil) and ultra‐long‐chain fat (DHA algae oil). When whey protein and casein were added in a 6:4 ratio, the effect of fatty acid carbon chain length on the average particle and the ...
Yanchen Liu+5 more
wiley +1 more source
The lipoprotein lipase of mammary gland and the correlation of its activity to lactation
The concentration of lipoprotein lipase of guinea pig mammary gland increases markedly just prior to parturition, reaching a maximal level within 2 hr post-partum.
O.W. McBride, Edward D. Korn
doaj
Lipoprotein Lipase Activity Does Not Differ in the Serum Environment of Vegans and Omnivores. [PDF]
Seeba NN, Risti R, Lõokene A.
europepmc +1 more source
Hydrolysis of chylomicron triacylglycerol by endothelium-bound lipoprotein lipase. Effect of decreased apoprotein C-II/C-III ratio [PDF]
T J Kotlar, Jayme Borensztajn
openalex +1 more source
Abstract Fenofibrate is contraindicated in patients with advanced hepatic fibrosis due to limited clinical data. We evaluated the pharmacokinetics and safety of fenofibrate in participants with mild hepatic impairment (phase 1 study) or advanced fibrosis due to metabolic‐associated fatty liver disease (MAFLD; phase 2a study).
Islam R. Younis+5 more
wiley +1 more source